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Abstract 
 MultiFlow® DNA Damage — p53, γH2AX, Phospho-Histone H3 is a miniaturized, flow 
cytometry-based assay that provides genotoxic mode of action information by distinguishing 
clastogens, aneugens, and non-genotoxicants. Work to date has focused on the p53-competent 
human cell line TK6. While mammalian cell genotoxicity assays typically supply exogenous 
metabolic activation in the form of concentrated rat liver S9, this is a less-than-ideal approach 
for several reasons, including 3Rs considerations. Here, we describe our experiences with low 
concentration S9 and saturating co-factors which were allowed to remain in contact with cells 
and test chemicals for 24 continuous hours. We exposed TK6 cells in 96-well plates to each of 
15 reference chemicals over a range of concentrations, both in the presence and absence of 
0.25% v/v phenobarbital/β-naphthoflavone-induced rat liver S9. After 4 and 24 hr of treatment 
cell aliquots were added to wells of a microtiter plate containing the working 
detergent/stain/antibody cocktail. After a brief incubation robotic sampling was employed for 
walk-away flow cytometric data acquisition. PROAST benchmark dose (BMD) modelling was 
used to characterize the resulting dose-response curves. For each of the 8 reference pro-
genotoxicants studied, relative nuclei count, γH2AX, and/or p53 biomarker BMD values were 
order(s) of magnitude lower for 0.25% S9 conditions compared to 0% S9. Conversely, several 
of the direct-acting reference chemicals exhibited appreciably lower cytotoxicity and/or 
genotoxicity BMD values in the presence of S9 (e.g., resorcinol). These results prove the 
efficacy of the low concentration S9 system, and indicate that an efficient and highly scalable 
multiplexed assay can effectively identify chemicals that require bioactivation to exert their 
genotoxic effects.  
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Introduction 
 Among the significant challenges associated with screening large numbers of chemicals 
for genotoxic potential is the low throughput capacity of conventional hazard identification-type 
assays. Progress is being made in this area, and includes miniaturization and automated 
scoring of: in vitro micronuclei [Bryce et al., 2010]; the alkaline comet assay [Ge et al., 2015]; 
γH2AX and other indicators of DNA damage [Audebert et al., 2010; Smart et al., 2011; Tsamou 
et al., 2012; Garcia-Canton et al., 2013; Nikolova et al., 2014; Cheung et al., 2015; Khoury et 
al., 2016]; a panel of five complementary high throughput screening assays described by Hsieh 
and colleagues [2019]; a toxicogenomic signature of genotoxicity [Li et al., 2015, 2017]; and 
fluorescent reporters of DNA damage and other cellular stress indicators using one or more 
engineered mammalian cell lines [Hastwell et al., 2006; Hendriks et al., 2012].  
Our work in this area includes development of the MultiFlow® DNA Damage Kit, an in 
vitro assay formatted as an add-and-read test that efficiently prepares mammalian cells in 
microtiter plates for flow cytometric analysis. The multiplexed biomarkers measured are: i) 
phosphorylation of H2AX at serine 139 (γH2AX) to detect DNA double strand breaks, ii) 
phosphorylation of histone H3 at serine 10 (p-H3) to identify mitotic cells, iii) nuclear p53 content 
as an indicator of p53 activation in response to DNA damage, iv) frequency of 8n+ cells to 
monitor polyploidization, and v) relative nuclei counts (RNC) to provide information about 
treatment-related cytotoxicity [Bryce et al., 2016]. 
 The MultiFlow assay has demonstrated good sensitivity and specificity for detecting 
diverse genotoxicants, and furthermore provides information about the predominant mode of 
genotoxic action—clastogenicity versus aneugenicity [Bryce et al., 2014, 2016, 2017, 2018; 
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Bernacki et al., 2016; Dertinger et al., 2019]. The bulk of the work to date has been 
accomplished with the p53-proficient human cell line TK6. Since TK6 cells do not have 
appreciable cytochrome P450 enzyme activities, they cannot reliably detect pro-genotoxicants 
unless an exogenous source of metabolic activation is added to the test system. Historically, in 
vitro genotoxicity assays are therefore tested in the presence and absence of rat liver 
microsomes (i.e., the so-called S9 fraction) with necessary cofactors [Ames et al., 1973].  
 Instead of using rat liver microsomes, some laboratories provide metabolic capacity by 
working with metabolically competent cells, typically of hepatocyte origin. However, many of 
these cell lines express low levels of important P450 isoforms, while others have good 
expression profiles but their proprietary nature adds costs that cannot always be accommodated 
in high volume- early screening-type environments [Westerink and Schoonen, 2007; Le Hégart 
et al., 2014].  
 For various reasons then, the use of high concentration rat liver S9 continues to be 
widely employed. However, there are several aspects that are less than ideal. First, the historic 
use of Aroclor-induced rat liver S9 has become problematic. The supply of Aroclor is nearly 
exhausted and it will not be replenished (personally communication, R. Cammeron, Molecular 
Toxicology, Inc). This means laboratories accustomed to using Aroclor-induced S9 will need to 
switch to an alternate induction scheme, for example phenobarbital/β-naphthoflavone, and 
ensure it is effective for their application(s). Second, the traditional use of high concentration S9 
(typically 2-4% v/v final) provides opportunities to reduce animal numbers, and thereby advance 
3Rs [Russell and Burch, 1959]. Third, high concentration S9 is inherently cytotoxic to cultured 
mammalian cells, and this explains why most protocols call for washing cells free of test 
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chemical and S9 enzymes after several hours of exposure. This is especially suboptimal in high 
throughput testing environments, since it is a subtraction step that is not as easily automated 
relative to processing steps that call for simple transfer(s) or addition(s). Finally, the requirement 
for centrifugation and aspiration has the potential to impact cell health and numbers which may 
be mistakenly attributed to test article toxicity as opposed to processing inconsistencies. 
 To address these issues with exogenous metabolic activation systems we investigated 
an alternate strategy based on phenobarbital/β-naphthoflavone-induced rat liver S9. Importantly, 
the final concentration of S9 was 0.25% v/v—the maximal non-cytotoxic concentration. Owing to 
the low cytotoxicity of the system, it was possible to maintain enzymes/co-factor mix with cells 
and test article for the complete exposure period (in the case of TK6-based MultiFlow assays, 
24 hr). This is similar to the approach used by the ToxTracker® system [Hendriks et al., 2012], 
where mouse stem cells are exposed to test article in the presence and absence of 0.25% 
Aroclor-induced rat S9 for 24 hr. For the initial proof-of-principle experiments described herein, 
we focused on clastogens, especially those that require enzymatic activation to most efficiently 
form DNA-reactive metabolites. Our encouraging experiences with the MultiFlow assay are 
described herein, along with a discussion about advantages of low concentration S9 
approaches.  
 
Materials and Methods 
Chemicals 
 The identity of the 15 test chemicals are provided in Table I, along with information about 
metabolic activation, predominant mode of action, etcetera. Most are specified in the European 
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Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) publication that lists 
chemicals that are useful for validating in vitro genotoxicity assays [Kirkland et al., 2016]. 
Importantly, the non-genotoxicants are cytotoxic to mammalian cells through a variety of 
mechanisms, and the pro-genotoxicants collectively require a diverse set of CYP450 enzymes 
to form DNA-reactive electrophiles. 
 
Cell Culture and Treatments 
 TK6 cells were purchased from ATCC® (cat. no. CRL-8015). Cells were grown in a 
humidified atmosphere at 37°C with 5% CO2, and were maintained at or below 1 x 106 cells/mL. 
The culture medium consisted of RPMI 1640 with 200 µg/mL sodium pyruvate (both from 
Sigma-Aldrich, St. Louis, MO), 200 µM L-glutamine, 50 units/mL penicillin and 50 µg/mL 
streptomycin (from Mediatech Inc., Manassas, VA), and 10% v/v heat-inactivated horse serum 
(Gibco®, a Thermo Fisher Scientific Company, Waltham, MA). 
 The low S9 concentration, continuous exposure activation approach utilized a NADPH 
regeneration system and frozen rat liver S9 from Molecular Toxicology Inc. (Boone, NC). 
Specifically, Regensys™ ‘A’ and Regensys™ ‘B’ reagents were combined, and this solution was 
used to prepare phenobarbital/β-naphthoflavone-induced rat liver S9 at a concentration of 2.5% 
v/v. This 10x solution was maintained on ice until it was added at a 1:9 ratio to TK6 cells 
adjusted to 2 x 105/mL in culture medium for a final S9 concentration of 0.25%. The 0% S9 
cultures were TK6 cells at 2 x 105/mL in culture medium culture medium without cofactors or S9.  
 Dose range-finding experiments were performed to generate 24 hr relative nuclei count 
(RNC) data for each chemical. Chemical treatments occurred in U-bottom 96 well plates, with 
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198 µL TK6 cell suspensions with and without S9/cofactor mix as described above. Test 
chemicals prepared in DMSO were added at 2 µL/well for final DMSO concentrations of 1% v/v. 
The highest test chemical concentration was 10 mM unless solubility or previous experience 
with a chemical indicated this would be overly cytotoxic. Testing occurred at 20 concentrations 
in single wells, and each concentration differed from the one above by a factor of 70.71%. 
Solvent was tested in at least 10 replicate wells spread throughout the plate. 
 Definitive experiments with the 15 test chemicals were also conducted in U-bottom 96 
well plates, with 198 µL TK6 cells with and without S9/cofactor mix as described above. As with 
the dose range-finding experiments, test chemicals prepared in DMSO were added at 2 µL/well. 
The highest concentration was derived from the dose range-finding experiment. In the case of 
non-cytotoxic freely soluble chemicals, the top concentration was 10 mM. When precipitate was 
evident, the lowest precipitating concentration was evaluated. Otherwise, our goal for the 
highest concentration tested was 60-80% reduction to RNC at 24 hr, but only two 
concentrations within the range 70-80% reduction were permitted [Dertinger et al., 2019]. The 
additional ten lower concentrations were tested using the 70.71% dilution scheme described 
above. Each of the 11 concentrations was tested in triplicate wells, whereas DMSO controls 
were evaluated in 10 replicate wells spread throughout the plate. Upon addition of test 
chemicals the plates were immediately incubated in a humidified atmosphere at 37°C with 5% 
CO2 for 24 hr.  
 Other experiments were performed with cyclophosphamide- and dibenzo[a,l]pyrene-
exposed TK6 cells in order to directly compare results from low, continuous S9 treatment versus 
a traditional approach to metabolic activation (i.e., short-term exposure with a high S9 
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concentration). The low, continuous S9 exposure occurred with 0.25% S9, and took place as 
described above. The short-term exposure with high concentration S9 was performed with the 
same rat liver S9 and cofactor mix, but in this case the final S9 concentration was 2% v/v, 
delivered from a 20% v/v stock solution. After 4 hr of treatment, cells were washed two times 
(via centrifugation, aspiration of 150 µL supernatants, and resuspension with phosphate 
buffered saline). After final resuspension with growth medium, the cells were reincubated for an 
additional 20 hr. 
  
MultiFlow Assay 
 For dose range-finding experiments, cells exposed to test chemicals for 4 and 24 hr 
were resuspended with pipetting, then 25 µL were removed from each well and added to a new 
96-well plate containing 50 µL/well of pre-aliquoted working MultiFlow reagent solution. This 
solution was prepared with reagents in the MultiFlow® DNA Damage Kit — p53, γH2AX, 
Phospho-Histone H3 (Litron Laboratories, Rochester, NY). Note that for these dose range-
finding experiments, antibodies were omitted from the reaction mix. In this manner, we 
simultaneously measured cytotoxicity (i.e., RNC values) as well as fluorescence in the p53 
and γH2AX channels for evidence of test article-associated fluorescence (“background 
fluorescence”) that could impact the definitive assay. After incubation at room temperature for 
30 min, samples were analyzed via flow cytometry. 
 For the definitive experiments, TK6 cells were prepared for analysis using reagents and 
instructions included in the MultiFlow® DNA Damage Kit — p53, γH2AX, Phospho-Histone H3. 
As with the dose range-finding experiments, at the 4 and 24 hr time points, an aliquot of 25 
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µL/well was added to wells containing 50 µL of pre-aliquoted working MultiFlow reagent solution 
without antibodies present. This was done for one of three replicate wells per concentration. 
Additionally, for each of the three replicate wells per concentration, an aliquot of 25 µL/well was 
added to wells containing 50 µL of pre-aliquoted working MultiFlow reagent solution with 
antibodies present. After incubation at room temperature for 30 min, samples were analyzed via 
flow cytometry.  
 Flow cytometric analysis was carried out using a Miltenyi Biotec MACSQuant® Analyzer 
10 flow cytometer with integrated 96-well MiniSampler device. Stock photomultiplier tube 
detectors and associated optical filter sets were used to detect fluorescence emissions 
associated with the fluorochromes: FITC (detected in the B1 channel, PE (B2 channel), 
propidium iodide (B3 channel), and Alexa Fluor® 647 (R1 channel).  
 Representative bivariate graphs, gating logic, and position of regions were described in 
detail in a previous report [Bryce et al., 2016]. Briefly, two biomarker measurements, γH2AX and 
p53, were based on the shift in median channel fluorescence intensity relative to same-plate 
solvent controls. Polyploidy and p-H3 biomarker measurements were based on their frequency 
among other nuclei. Nuclei to counting bead ratios were calculated for each sample, and these 
ratios were used to determine absolute nuclei counts (those with 2n and greater DNA-
associated propidium iodide fluorescence). Nuclei counts were used to derive RNC, and 
%cytotoxicity was calculated as 100% minus %RNC at 24 hr for each concentration tested. 
 
MultiFlow Data Analysis: Pre-Processing 
  Definitive study MultiFlow data were corrected for background fluorescence in those 
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rare instances when test chemical alone, in the absence of fluorescent antibodies, shifted the 
median channel fluorescence of the p53 and/or γH2AX biomarkers relative to solvent control 
wells. This was accomplished in a test chemical- and concentration-specific manner by 
subtracting the mean solvent control median fluorescence value (no antibodies present) from 
the median fluorescent value (antibodies present) observed at each test article concentration. 
This value corresponds to fluorescence that cannot be attributed to antibody reagents, and was 
subtracted from the corresponding median fluorescence channel observed at the same 
concentration in the presence of the complete labeling solution, that is, the reagent mix that 
included antibodies.  
 After baseline fluorescence corrections as necessary, MultiFlow data were prepared for 
analysis by converting 4 and 24 hr γH2AX and p53 median fluorescence values, and p-H3 and 
polyploidy frequency measurements, into fold-change values. This was accomplished on an 
endpoint-, well-, and time point-specific basis by dividing the biomarker measurement by the 
mean solvent control value (Microsoft Excel, v16.16.14). This was performed for every test 
article concentration that was not excluded due to excessive cytotoxicity or other limits 
described above.  
 
MultiFlow Data Analysis: Machine Learning Ensemble 
 The use of three ML models, multinomial logistic regression (LR), artificial neural 
network (ANN), and random forest (RF), has been described in detail previously [Bryce et al., 
2018]. These various models utilize 4 and 24 hr MultiFlow data fold-change values and predict 
whether a chemical exhibits clastogenic, aneugenic, or clastogenic and aneugenic activity. Each 
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model’s output was synthesized into MoA calls as follows. A clastogenic MoA required two 
successive concentrations to exhibit clastogen probability scores ≥ 80%, or one concentration to 
exhibit a clastogen probability score ≥ 90%. An aneugen MoA required two successive 
concentrations to exhibit aneugen probability scores ≥ 80%, or one concentration to exhibit an 
aneugen probability score ≥ 90%. Non-genotoxic was defined as the absence of two successive 
concentrations exhibiting clastogen or aneugen probability scores ≥ 80%, and no single 
concentration exhibiting a clastogen or aneugen probability score ≥ 90%. 
 Results from the three clastogen models were synthesized into a final prediction based 
on a majority vote ensemble. That is, a simple majority (≥ 2/3 clastogen-positive models) was 
necessary for a final clastogen call. (Note that since the experiments described herein focused 
on metabolic activation and clastogenicity, and because no aneugen probability scores ≥ 80% 
were observed, data for the aneugen-responsive biomarkers (p-H3 and polyploidy) and 
aneugen machine learning probabilities are not presented.)  
 
MultiFlow Data Analysis: BMD Analyses 
  Benchmark dose (BMD) analyses [Wills et al., 2015] were performed for several 
MultiFlow biomarker responses using PROAST v67.0, which was accessed through the 
European Food Safety Authority online tool, see: 
https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/sp.efsa.2019.EN-1489. Critical Effect Size 
(CES) values were -0.3 for the %RNC endpoint (i.e., 30% reduction), and 0.3 for fold-change 
p53 and γH2AX endpoints (i.e., 30% increase). One chemical at a time was analyzed, with the 
S9 condition as the covariate. With very few exceptions, an exponential model was used to fit 
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the dose response curves. To facilitate potency comparisons across S9 conditions, BMD values 
are reported for all chemicals, biomarkers, and time points. In those cases where PROAST 
could not reliably fit a model (i.e., because a response did not reach the specified CES), or 
where the BMD estimate was beyond the top concentration tested, we cited the BMD as the top 
concentration tested with a greater than symbol. BMD values for with and without S9 were used 
to derive a “S9 Potentiation Ratio”, which is the BMD value in the absence of S9 divided by the 
BMD value in the presence of S9. For example, a value of 10 corresponds to 
chemical/biomarker/time point combination exhibiting 10-fold higher potency in the presence of 
S9, whereas a value of 0.1 corresponds 10-fold reduced potency in the presence of S9. 
 
Results and Discussion 
Preliminary Experiments 
 Early work focused on determining the maximal amount of rat liver S9 that could be 
tolerated by TK6 cells for 24 hr without causing significant cytotoxicity. Where S9 concentrations 
≥ 0.5% showed evidence of cytotoxicity as expressed by reduced %RNC and increased 
frequencies of cells with impaired membrane integrity, 0.25% S9 in combination with 10% v/v 
cofactor mix had little to no effect (data not shown). This is consistent with the ToxTracker 
protocol that utilizes 0.25% S9 for mouse stem cell experiments, and explains our use of 0.25% 
for the experiments that followed.   
 Other experiments were performed to directly compare results generated by the low 
(0.25%) S9 approach to those based on traditional short-term treatment with a high S9 
concentration. As shown by Figure 1, CP caused robust γH2AX and p53 responses that 
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correctly classified the agent as clastogenic. The 24 hr γH2AX and p53 responses were 
remarkably similar across the S9 systems. On the other hand, several significant differences 
were evident for other biomarkers/time points. For instance, appreciably greater cytotoxicity 
(reduced RNC) was evident at lower concentrations when 2% S9 was used. Also, the RNC 
values for replicate 2% S9 wells were more variable compared to the low S9 approach, likely 
due to the additional cell processing steps that were necessary. We quantified the extent of 
RNC variation by considering the ratio between the BMD upper confidence limit (BMDU) to the 
BMD lower confidence limit (BMDL) [Wills et al., 2015]. Whereas this ratio was low for the 
continuous S9 cultures (8.09 / 5.89 or 1.4), it was considerably higher for the 2% S9 cultures 
that required washout (1.67 / 0.0774 or 22). Finally, whereas the magnitude of 4 hr γH2AX 
responses were similar between low and high concentration S9, the latter’s dose response 
curve was shifted to the left.  
 Figure 2 shows results for TK6 cells exposed to DB[a,l]P with low, continuous S9 versus 
the standard short-term 2% approach. Again, both systems produced clear γH2AX and p53 
responses that correctly classified DB[a,l]P as clastogenic. The RNC dose response curves 
were quite similar, although replicate wells were more variable for high concentration S9. 
(BMDU to BMDL ratios = 1.8 and 10.7 for continuous S9 versus washout S9, respectively.) 
Whereas the 4 hr γH2AX dose response curve was shifted slightly to the left for the high S9 
condition, the reverse was true for 24 hr γH2AX and p53 curves. Furthermore, 24 hr γH2AX and 
p53 responses exhibited markedly higher magnitudes in the low, continuous S9 system. 
 Pilot studies with B[a]P are noteworthy, as they alerted us to the possibility that some test 
chemicals can impart fluorescence to detergent-liberated nuclei that may affect one or both 
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biomarkers that are based on median fluorescence, i.e., p53 and γH2AX. Figure 3 shows 24 hr 
p53 results over a range of B[a]P concentrations. Since nuclei that were not brought into contact 
with antibodies exhibited increasing fluorescence with increasing B[a]P concentration, this effect 
must be attributed to background fluorescence, not the p53 biomarker. Once background 
fluorescence is subtracted from the values obtained with antibodies present, a more accurate 
assessment of the biomarker is made. For the experiments described herein, background 
fluorescence was only appreciable for three chemicals (2AAN, B[a]P, and brefeldin A) and the 
one biomarker read on the FITC channel, i.e., p53. 
 Given the promising preliminary results described above, we proceeded to test 15 
reference chemicals with and without the low concentration S9 system.  
 
2AAF 
 Results for 2AAF are provided in Figure 4. The presence of S9 did not remarkably affect 
cytotoxicity as expressed as %RNC, and no substantial effects on the p53 biomarker were 
observed. On the other hand, γH2AX clearly responded at the 4 and 24 hr time points when S9 
was present, and these were of sufficient magnitude for the machine learning ensemble to 
characterize 2AAF +S9 as clastogenic. Although a modest γH2AX effect was apparent at 4 hr 
without S9, it was not sufficient for a clastogen call. Based on BMD estimates, S9 potentiated 
early and late γH2AX responses by approximately 2.6- and 8.9-fold, respectively (Table II). 
 
2AAN 
 2AAN results are shown in Figure 5. The presence of S9 potentiated 24 hr %RNC, as well 
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as p53 and γH2AX induction at both time points studied. The machine learning ensemble 
characterized 2AAN +S9 as clastogenic. The γH2AX responses at the 4 and 24 hr time points 
without S9 were of sufficient magnitudes for the machine learning ensemble to make a 
clastogenic call for this condition as well. That being said, Table II highlights the fact the 
presence of S9 resulted in 1 - 2 orders of magnitude higher potency compared to no S9, for 
example 167-fold more potent in the case of 4 hr γH2AX. 
 
Anisomycin 
 Anisomycin caused concentration-dependent reductions to RNC, and as shown by Figure 
6, the presence of S9 muted the effect. In fact, as shown by Table II, the largest effect S9 had 
on Anisomycin was this S9-related protection effect on %RNC. The genotoxicity biomarkers did 
not respond to any appreciable level, with the exception of a slight increase in 24 hr γH2AX at 
the highest concentrations tested in cultures without S9. As shown by the machine learning 
graph, this weak effect did not result in a clastogen prediction, with or without S9.  
 
B[a]P 
 Results for B[a]P are provided in Figure 7. In the presence of S9, B[a]P caused 
concentration-dependent reductions to RNC, whereas cultures without S9 showed no signs of 
cytotoxicity up to the lowest precipitating concentration. Whereas 4hr p53 responses in the 
presence of S9 were minimal, robust effects were observed for 24 hr p53 as well as the γH2AX 
biomarker at both time points. The machine learning ensemble characterized B[a]P +S9 as 
clastogenic. Cultures without S9 showed modestly elevated γH2AX fluorescence at 24 hr, just 
This article is protected by copyright. All rights reserved.
enough for the machine learning algorithms to characterize B[a]P without S9 as clastogenic. 
Table II puts this into perspective—several orders of magnitude higher concentrations of B[a]P 
were required in the absence of S9 to exert this effect.  
 
Brefeldin A 
 Brefeldin A caused concentration-dependent reductions to RNC, and as shown by Figure 
8, S9 attenuated the effect. In fact, as shown by Table II, the presence of S9 shifted the BMD by 
approximately 100-fold. The genotoxicity biomarkers were unresponsive despite the 
considerable cytotoxicity that was induced, and as shown by the machine learning graph, 
neither the 0 or 0.25% S9 treatment scenario resulted in a clastogen prediction. 
 
CCCP 
 Results for CCCP are provided in Figure 9. CCCP caused concentration-dependent 
reductions to RNC, and the absence of S9 shifted the curve to the left, approximately halving 
the BMD value (Table II). The genotoxicity biomarkers did not respond to any appreciable level, 
with the exception of a modest increase in 24 hr p53 in cultures with S9. Even so, as shown by 
the machine learning graph, this effect did not lead to a clastogen prediction. 
 
CP 
 CP caused concentration-dependent reductions to RNC both in the presence and absence 
of S9 (Figure 10). However, as shown by Table II, it required on the order of 800x lower CP 
concentration to achieve the CES when 0.25% S9 was provided. In the presence of S9, CP 
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induced large increases to γH2AX at both time points, and p53 at 24 hr. In the absence of S9, 
CP exhibited weaker effects, both in terms of BMD values and biomarker response magnitudes. 
Indeed, Table II shows that the genotoxicity biomarkers exhibited between 2- and 3-orders of 
magnitude lower BMD values when low concentration S9 was included for 24 hr. Even so, the 
machine learning ensemble characterized CP, both with and without S9, as clastogenic.  
 
Cycloheximide 
 Results for cycloheximide are provided in Figure 11. Cycloheximide caused concentration-
dependent reductions to RNC, and S9 only slightly affected the BMD value (Table II). The 
genotoxicity biomarkers did not respond to any appreciable level, with the exception of a modest 
increase in 24 hr γH2AX in cultures lacking S9. However, as shown by the machine learning 
graph, cycloheximide was not predicted to be clastogenic, either with or without S9. 
 
DB[a,l]P 
 Results for DB[a,l]P are provided in Figure 12. The presence of S9 caused concentration-
dependent reductions to RNC, while cultures without S9 showed no signs of cytotoxicity up to 
the lowest precipitating concentration. Whereas 4 hr p53 exhibited a slight response in the 
presence of S9, late p53 and γH2AX at both time points showed large increases. Similar patters 
were observed in cultures exposed to DB[a,l]P without S9, but in each case the magnitude of 
the response was greatly reduced, and the concentrations required to reach the CES were 
much higher. Indeed, Table II shows that for the most responsive biomarker (γH2AX at 24 hr), 
0.25% S9 increased DB[a,l]P’s potency by 4 orders of magnitude. The machine learning 
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predictions characterized DB[a,l]P, with and without S9, as clastogenic. 
 
DEN 
 DEN results are shown in Figure 13. The presence of 0.25% S9 increased cytotoxicity, 
and furthermore potentiated γH2AX responses by more than 3.5- and 10-fold at the 4 and 24 hr 
time points, respectively (Table II). The machine learning ensemble characterized DEN +S9 as 
clastogenic, but not until high mM concentrations were reached. On the other hand, even up to 
the 10 mM limit concentration, in the absence of S9 DEN did not trigger a genotoxic prediction 
by any of the three machine learning models.  
 
DMBA 
 Results for DMBA are provided in Figure 14. Concentration-dependent reductions to RNC 
were observed both with and without S9, however, the presence of S9 made DMBA a much 
more potent cytotoxicant (21.8-fold difference in potency, Table II). DMBA +S9 exhibited robust 
p53 responses at both time points, as well as γH2AX at 4 hr. Whereas DMBA -S9 caused an 
early γH2AX effect and late p53 induction, the magnitude of the responses were reduced, and 
the concentrations required to reach the CES were much higher. For instance, as shown in 
Table II, the 4 hr γH2AX biomarker exhibited 89-fold difference in potency between the 0 and 
0.25% S9 conditions. The machine learning predictions characterized DMBA clastogenic, both 
in the presence and absence of S9.   
 
MMC 
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 MMC caused concentration-dependent reductions to RNC both in the presence and 
absence of S9 (Figure 15), with 0.25% S9 slightly attenuating the cytotoxic effect. The p53 and 
γH2AX biomarkers markedly responded in a concentration-dependent manner at both time 
points, with and without S9. As shown by Table II, the ability of MMC to induce p53 and γH2AX 
tended to be slightly but consistently lower in the presence of S9. The machine learning 
ensemble characterized MMC, with and without S9, as clastogenic. 
 
PhIP 
 Results for PhIP are provided in Figure 16. The presence of S9 caused concentration-
dependent reductions to RNC, whereas cultures without S9 showed no signs of cytotoxicity up 
to the lowest precipitating concentration. Whereas the p53 and γH2AX biomarkers were highly 
responsive in the presence of 0.25% S9, no appreciable effects were observed without S9. It is 
therefore not surprising that Table II characterizes the potency of PhIP with S9 to be at least 3 
orders of magnitude greater in the presence as opposed to the absence of S9, at least for the 4 
hr γH2AX biomarker. The machine learning ensemble predicted PhIP +S9 to be clastogenic, 
whereas -S9 did not trigger a clastogen call.  
 
Resorcinol 
 Resorcinol caused concentration-dependent reductions to RNC both in the presence and 
absence of S9 (Figure 17), with a considerable attenuating effect in the presence of 0.25% S9. 
Whereas the p53 responses were modest at 4 hr, strong induction of p53 with and without S9 
occurred at 24 hr. The magnitudes of the γH2AX biomarker responses were pronounced at both 
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time points, and similar across S9 conditions. That being said, S9 markedly shifted the dose 
response curves to the right. Table II highlights this effect on BMD values, which were reduced 
by the presence of S9 by an order of magnitude in several instances. The machine learning 
ensemble characterized resorcinol, with and without S9, as clastogenic. 
 
Thapsigargin 
 Results for thapsigargin are provided in Figure 18. Thapsigargin caused concentration-
dependent reductions to RNC, with similar profiles occurring with and without S9. The 
genotoxicity biomarkers did not respond to any appreciable level. As shown by the machine 
learning graph, thapsigargin was not predicted to be clastogenic, despite the significant levels of 
cytotoxicity that were induced.  
 
Conclusions 
 The results of the experiments described herein clearly support the use of 0.25% 
phenobarbital/β-naphthoflavone-induced rat liver S9 in combination with a NADPH regeneration 
system as a means to detect chemicals that require enzymatic activation to exert their genotoxic 
effects. Each of the 8 genotoxicants that are known to be enzymatically metabolized to more 
reactive electrophiles were found to be clastogenic in this system. In the instances these 
chemicals were positive with and without S9, the genotoxic potencies were increased by 
order(s) of magnitude in the presence of 0.25% S9.  
 Importantly, the 0.25% concentration utilized by the ToxTracker test and evaluated herein 
with the MultiFlow assay is non-cytotoxic to TK6 cells over an extended time frame (at least 24 
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hr). This concentration is on the order of 8- to 10-times lower than those that have been 
traditionally used, and therefore clearly address 3Rs goals. The low concentration also 
facilitated the continuous exposure scenario that appears to be a large contributor to the 
effectiveness of the system, as most of the observed genotoxic effects were markedly higher at 
the later (24 hr) time point. Furthermore, the ability to conduct the assay without the need for 
centrifugation and aspiration steps benefitted the system in at least two other significant ways. 
First, the data were collected in a more efficient manner, with a clear potential for fully 
automated cell processing. Second, the cytotoxicity measurements for replicate wells were less 
variable, likely attributable to the fewer processing steps required. This suggests the data were 
not simply being acquired more efficiently, but also in a more reliable and reproducible manner. 
 Ideally, the encouraging results presented here will stimulate additional work that 
evaluates the transferability of the low S9 strategy to other laboratories, and investigates the 
generalizability of the method to other cell lines and endpoints.  
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Figure Legends  
Figure 1. MultiFlow results are shown for TK6 cells exposed to cyclophosphamide in the 
presence of 2% S9 that was washed out after 4 hours (red Xs), or in the presence of 0.25% S9 
for 24 continuous hours (black triangles). Note that large symbols denote averages, and small 
symbols represent data for individual replicate wells. Relative Nuclei Counts (RNC), p53, and 
γH2AX data were modeled with PROAST software to provide Benchmark Dose estimates based 
on Critical Effect Sizes of -0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine 
learning probabilities based on Random Forest (RF), Logistic Regression (LR), and Neural 
Network (NN) models.      
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Figure 2. MultiFlow results are shown for TK6 cells exposed to dibenzo[a,l]pyrene in the 
presence of 2% S9 that was washed out after 4 hours (red Xs), or in the presence of 0.25% S9 
for 24 continuous hours (black triangles). Note that large symbols denote averages, and small 
symbols represent data for individual replicate wells. Relative Nuclei Counts (RNC), p53, and 
γH2AX data were modeled with PROAST software to provide Benchmark Dose estimates based 
on Critical Effect Sizes of -0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine 
learning probabilities based on Random Forest (RF), Logistic Regression (LR), and Neural 
Network (NN) models.    
 
Figure 3. MultiFlow p53 results are shown for TK6 cells exposed to benzo[a]pyrene in the 
presence of 0.25% S9 for 24 continuous hours. Whereas red triangles correspond to 
fluorescence obtained with fluorescent antibodies against p53, black circles are results 
observed when no antibodies were included in the reaction mix. The increased fluorescence 
observed with increasing concentrations of benzo[a]pyrene in the ‘no antibodies’ samples 
therefore corresponds to test article-associated background fluorescence, and these data were 
used to correct for this phenomenon (blue triangles).       
 
Figure 4. MultiFlow results are shown for TK6 cells exposed to 2-acetylaminofluorene in the 
absence of S9 (red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black 
triangles). Note that large symbols denote averages, and small symbols represent data for 
individual replicate wells. Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled 
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with PROAST software to provide Benchmark Dose estimates based on Critical Effect Sizes of -
0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine learning probabilities 
based on Random Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.  
 
Figure 5. MultiFlow results are shown for TK6 cells exposed to 2-amminoanthracene in the 
absence of S9 (red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black 
triangles). Note that large symbols denote averages, and small symbols represent data for 
individual replicate wells. Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled 
with PROAST software to provide Benchmark Dose estimates based on Critical Effect Sizes of -
0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine learning probabilities 
based on Random Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.  
 
Figure 6. MultiFlow results are shown for TK6 cells exposed to anisomycin in the absence of S9 
(red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black triangles). Note that 
large symbols denote averages, and small symbols represent data for individual replicate wells. 
Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled with PROAST software to 
provide Benchmark Dose estimates based on Critical Effect Sizes of -0.3, 0.3 and 0.3, 
respectively. The upper-right graph shows machine learning probabilities based on Random 
Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.    
 
Figure 7. MultiFlow results are shown for TK6 cells exposed to benzo[a]pyrene in the absence 
of S9 (red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black triangles). Note 
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that large symbols denote averages, and small symbols represent data for individual replicate 
wells. Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled with PROAST 
software to provide Benchmark Dose estimates based on Critical Effect Sizes of -0.3, 0.3 and 
0.3, respectively. The upper-right graph shows machine learning probabilities based on Random 
Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.     
 
Figure 8. MultiFlow results are shown for TK6 cells exposed to brefeldin A in the absence of S9 
(red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black triangles). Note that 
large symbols denote averages, and small symbols represent data for individual replicate wells. 
Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled with PROAST software to 
provide Benchmark Dose estimates based on Critical Effect Sizes of -0.3, 0.3 and 0.3, 
respectively. The upper-right graph shows machine learning probabilities based on Random 
Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.      
 
Figure 9. MultiFlow results are shown for TK6 cells exposed to carbonyl cyanide m-
chlorophenyl hydrazine in the absence of S9 (red Xs), or in the presence of 0.25% S9 for 24 
continuous hours (black triangles). Note that large symbols denote averages, and small symbols 
represent data for individual replicate wells. Relative Nuclei Counts (RNC), p53, and γH2AX 
data were modeled with PROAST software to provide Benchmark Dose estimates based on 
Critical Effect Sizes of -0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine 
learning probabilities based on Random Forest (RF), Logistic Regression (LR), and Neural 
Network (NN) models.     
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Figure 10. MultiFlow results are shown for TK6 cells exposed to cyclophosphamide in the 
absence of S9 (red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black 
triangles). Note that large symbols denote averages, and small symbols represent data for 
individual replicate wells. Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled 
with PROAST software to provide Benchmark Dose estimates based on Critical Effect Sizes of -
0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine learning probabilities 
based on Random Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.    
 
Figure 11. MultiFlow results are shown for TK6 cells exposed to cycloheximide in the absence 
of S9 (red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black triangles). Note 
that large symbols denote averages, and small symbols represent data for individual replicate 
wells. Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled with PROAST 
software to provide Benchmark Dose estimates based on Critical Effect Sizes of -0.3, 0.3 and 
0.3, respectively. The upper-right graph shows machine learning probabilities based on Random 
Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.  
 
Figure 12. MultiFlow results are shown for TK6 cells exposed to dibenzo[a,l]pryene in the 
absence of S9 (red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black 
triangles). Note that large symbols denote averages, and small symbols represent data for 
individual replicate wells. Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled 
with PROAST software to provide Benchmark Dose estimates based on Critical Effect Sizes of -
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0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine learning probabilities 
based on Random Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.  
 
Figure 13. MultiFlow results are shown for TK6 cells exposed to diethylnitrosamine in the 
absence of S9 (red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black 
triangles). Note that large symbols denote averages, and small symbols represent data for 
individual replicate wells. Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled 
with PROAST software to provide Benchmark Dose estimates based on Critical Effect Sizes of -
0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine learning probabilities 
based on Random Forest (RF), Logistic Regression (LR), and Neural Network (NN) models. 
 
Figure 14. MultiFlow results are shown for TK6 cells exposed to 7,12-
dimethylbenz[a]anthracene in the absence of S9 (red Xs), or in the presence of 0.25% S9 for 24 
continuous hours (black triangles). Note that large symbols denote averages, and small symbols 
represent data for individual replicate wells. Relative Nuclei Counts (RNC), p53, and γH2AX 
data were modeled with PROAST software to provide Benchmark Dose estimates based on 
Critical Effect Sizes of -0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine 
learning probabilities based on Random Forest (RF), Logistic Regression (LR), and Neural 
Network (NN) models.  
 
Figure 15. MultiFlow results are shown for TK6 cells exposed to mitomycin C in the absence of 
S9 (red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black triangles). Note that 
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large symbols denote averages, and small symbols represent data for individual replicate wells. 
Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled with PROAST software to 
provide Benchmark Dose estimates based on Critical Effect Sizes of -0.3, 0.3 and 0.3, 
respectively. The upper-right graph shows machine learning probabilities based on Random 
Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.   
 
Figure 16. MultiFlow results are shown for TK6 cells exposed to 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine in the absence of S9 (red Xs), or in the presence of 0.25% S9 for 
24 continuous hours (black triangles). Note that large symbols denote averages, and small 
symbols represent data for individual replicate wells. Relative Nuclei Counts (RNC), p53, and 
γH2AX data were modeled with PROAST software to provide Benchmark Dose estimates based 
on Critical Effect Sizes of -0.3, 0.3 and 0.3, respectively. The upper-right graph shows machine 
learning probabilities based on Random Forest (RF), Logistic Regression (LR), and Neural 
Network (NN) models. 
 
Figure 17. MultiFlow results are shown for TK6 cells exposed to resorcinol in the absence of S9 
(red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black triangles). Note that 
large symbols denote averages, and small symbols represent data for individual replicate wells. 
Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled with PROAST software to 
provide Benchmark Dose estimates based on Critical Effect Sizes of -0.3, 0.3 and 0.3, 
respectively. The upper-right graph shows machine learning probabilities based on Random 
Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.     
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Figure 18. MultiFlow results are shown for TK6 cells exposed to thapsigargin in the absence of 
S9 (red Xs), or in the presence of 0.25% S9 for 24 continuous hours (black triangles). Note that 
large symbols denote averages, and small symbols represent data for individual replicate wells. 
Relative Nuclei Counts (RNC), p53, and γH2AX data were modeled with PROAST software to 
provide Benchmark Dose estimates based on Critical Effect Sizes of -0.3, 0.3 and 0.3, 
respectively. The upper-right graph shows machine learning probabilities based on Random 
Forest (RF), Logistic Regression (LR), and Neural Network (NN) models.  
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Table II. Benchmark Dose Estimates.  
 
BMD (µM) 
Treatment 4hr p53 24hr p53 4hr γH2AX 24hr γH2AX 24hr RNC 
      2AAF without S9 >311 >311 >311 >311 98 
2AAF with S9 >311 >311 119 35 184 
S9 Potentiation Ratio NC NC >2.6 >8.9 0.53 
      2AAN without S9 >55 >55 40 10.9 >55 
2AAN with S9 7.9 2.5 0.24 0.67 2.1 
S9 Potentiation Ratio 7 >22 167 16.3 >26.2 
      Anisomycin without S9 >2.5 >2.5 >2.5 2.1 0.08 
Anisomycin with S9 >14.1 >14.1 >14.1 >14.1 0.48 
S9 Potentiation Ratio NC NC NC <0.15 0.17 
      B[a]P without S9 >88 >88 >88 36 >88 
B[a]P with S9 >31 1.1 0.19 2x10^-5 2.8 
S9 Potentiation Ratio NC >80 >463 1.8x10^6 >31.4 
      Brefeldin A without S9 >0.5 >0.5 >0.5 >0.5 0.13 
Brefeldin A with S9 >356 >356 >356 >356 12.8 
S9 Potentiation Ratio NC NC NC NC 0.01 
      CCCP without S9 >35 >35 >35 >35 2.0 
CCCP with S9 >35 26 >35 >35 4.4 
S9 Potentiation Ratio NC >1.3 NC NC 0.45 
      CP without S9 >10,000 7,570 >10,000 5,523 5,981 
CP with S9 >156 8.7 99 1.7 7.5 
S9 Potentiation Ratio NC 870 >101 3,249 797 
      Cycloheximide without 
S9 >15 >15 >15 12 0.25 
Cycloheximide with S9 >15 >15 >15 >15 0.31 
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S9 Potentiation Ratio NC NC NC <0.8 0.8 
      DB(a,l)P without S9 >50 >50 25 >50 >50 
DB(a,l)P with S9 0.9 0.052 0.0011 0.0013 0.041 
S9 Potentiation Ratio >56 >962 22,727 >38,462 >1,220 
      DEN without S9 >10,000 >10,000 >10,000 >10,000 >10,000 
DEN with S9 >10,000 >10,000 2,867 1,004 >10,000 
S9 Potentiation Ratio NC NC >3.5 >10 NC 
      DMBA without S9 >194 116 13.3 >194 98 
DMBA with S9 5.9 4.9 0.15 >194 4.5 
S9 Potentiation Ratio >32.9 23.7 88.7' NC 21.8 
      MMC without S9 0.802 0.0988 0.05031 0.00862 0.07407 
MMC with S9 1.576 0.136 0.06122 0.03391 0.2363 
S9 Potentiation Ratio 0.51 0.73 0.82 0.25 0.31 
      PhIP without S9 >178 >178 >178 >178 >178 
PhIP with S9 56.81 5.142 0.1093 0.2281 9.764 
S9 Potentiation Ratio >3.1 >34.6 >1,629 >780 >18.2 
      Resorcinol without S9 >12.5 2.6 6.6 0.79 0.59 
Resorcinol with S9 >71 24.6 25.8 14.4 12.6 
S9 Potentiation Ratio NC 0.11 0.26 0.05 0.047 
      Thapsigargin without S9 >21 >21 >21 >21 0.2 
Thapsigargin with S9 >15 >15 >15 >15 0.14 
S9 Potentiation Ratio NC NC NC NC 1.4 
 
--------- 
Abbreviations: Chemical abbreviations = same as Table I; BMD = benchmark dose; 
RNC = relative nuclei count; NC = not calculated 
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Table I. Test chemicals, source, biological effects.  




Miscellaneous Info  
References 
2-Acetylaminofluorene (2AAF) 53-96-3, 
Sigma-Aldrich 
Clastogen, requires metabolic 
activation (CYP1A2), forms C8 
adduct on guanine 
Otteneder and Lutz, 
1999; Kirkland et al., 
2016 
2-Aminoanthracene (2AAN) 613-13-8, 
Sigma-Aldrich 
Clastogen, aromatic amine, 
requires metabolic activation 
(CYP1B1, 2A family) 
Carriére et al., 1992 
Anisomycin 22862-76-6, 
Sigma-Aldrich 
Cytotoxicant, protein synthesis 
inhibitor; in vitro MN neg. with 






Benzo[a]pyrene (B[a]P) 50-32-8, 
Sigma-Aldrich 
Clastogen, polycyclic aromatic 
hyrocarbon, requires metabolic 
activation (CYP1A1, 1B1, 
epoxide hydrolase), forms 
bulky adducts 
Kirkland et al., 2016 
Brefeldin A  20350-15-6, 
Sigma-Aldrich 
Cytotoxicant, ER-golgi 
transporter inhibitor, ER 
stress-induced apoptosis 













Clastogen, nitrogen mustard, 
requires metabolic activation 
(CYP2B6, CYP2C19, CYP2C9 
and CYP3A4/5) 






Cytotoxicant, protein synthesis 
inhibitor 
Youngblom et al., 
1989 
This article is protected by copyright. All rights reserved.
Dibenzo[a,l]pyrene (DB[a,l]P) 191-30-0, 
Sigma-Aldrich 
 
Clastogen, polycyclic aromatic 
hydrocarbon, requires 
metabolic activation (thought 
to be primarily activated by 
CYP1A1) 
Arif and Gupta, 1997 
Diethylnitrosamine (DEN) 55-18-5, 
Sigma-Aldrich 
Clastogen, requires metabolic 
activation to form alkylating 
agent (likely involves CYP2E1 
which is not highly expressed 
in rat liver S9); often only 
positive at high concentrations 
(≥10 mM) 






Clastogen, requires metabolic 
activation (CYP1B1), forms 
bulky adducts  
Kirkland et al., 2016 
Mitomycin C (MMC) 50-07-7, 
Sigma-Aldrich 
DNA-DNA crosslinks, also 
alkylating activity and oxidative 
damage 








Clastogen, heterocyclic amine, 
requires metabolic activation 
(CYP1A family) 
Kirkland et al., 2016; 
Krais et al., 2016 
Resorcinol 108-46-3, 
Sigma-Aldrich 
In vitro mammalian cell pos. 
(MLA assay with and without 
metabolic activation pos., in 
vitro human lymphocyte MN 
pos. in absence of metabolic 
activation); in vitro findings not 
confirmed in vivo (mouse MN 
neg.) 
EFSA Journal, 2010 




Futami et al., 2005 
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Table I. Test chemicals, source, biological effects.  




Miscellaneous Info  
References 
2-Acetylaminofluorene (2AAF) 53-96-3, 
Sigma-Aldrich 
Clastogen, requires metabolic 
activation (CYP1A2), forms C8 
adduct on guanine 
Otteneder and Lutz, 
1999; Kirkland et al., 
2016 
2-Aminoanthracene (2AAN) 613-13-8, 
Sigma-Aldrich 
Clastogen, aromatic amine, 
requires metabolic activation 
(CYP1B1, 2A family) 
Carriére et al., 1992 
Anisomycin 22862-76-6, 
Sigma-Aldrich 
Cytotoxicant, protein synthesis 
inhibitor; in vitro MN neg. with 




Spellman, Maria Engel 
Benzo[a]pyrene (B[a]P) 50-32-8, 
Sigma-Aldrich 
Clastogen, polycyclic aromatic 
hyrocarbon, requires metabolic 
activation (CYP1A1, 1B1, 
epoxide hydrolase), forms bulky 
adducts 
Kirkland et al., 2016 
Brefeldin A  20350-15-6, 
Sigma-Aldrich 
Cytotoxicant, ER-golgi 
transporter inhibitor, ER stress-
induced apoptosis 













Clastogen, nitrogen mustard, 
requires metabolic activation 
(CYP2B6, CYP2C19, CYP2C9 
and CYP3A4/5) 






Cytotoxicant, protein synthesis 
inhibitor 
Youngblom et al., 
1989 
Dibenzo[a,l]pyrene (DB[a,l]P) 191-30-0, 
Sigma-Aldrich 
 
Clastogen, polycyclic aromatic 
hydrocarbon, requires metabolic 
activation (thought to be 
primarily activated by CYP1A1) 
Arif and Gupta, 1997 
Diethylnitrosamine (DEN) 55-18-5, 
Sigma-Aldrich 
Clastogen, requires metabolic 
activation to form alkylating 
agent (likely involves CYP2E1 
which is not highly expressed in 
rat liver S9); often only positive 
Yamazaki et al., 1992;  
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Clastogen, requires metabolic 
activation (CYP1B1), forms 
bulky adducts  
Kirkland et al., 2016 
Mitomycin C (MMC) 50-07-7, 
Sigma-Aldrich 
DNA-DNA crosslinks, also 
alkylating activity and oxidative 
damage 








Clastogen, heterocyclic amine, 
requires metabolic activation 
(CYP1A family) 
Kirkland et al., 2016; 
Krais et al., 2016 
Resorcinol 108-46-3, 
Sigma-Aldrich 
In vitro mammalian cell pos. 
(MLA assay with and without 
metabolic activation pos., in vitro 
human lymphocyte MN pos. in 
absence of metabolic activation); 
in vitro findings not confirmed in 
vivo (mouse MN neg.) 
EFSA Journal, 2010 
Thapsigargin  67526-95-8, 
Sigma-Aldrich 
Cytotoxicant, ER stress-induced 
apoptosis 
Futami et al., 2005 
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Table II. Benchmark Dose Estimates.  
 
BMD (µM) 
Treatment 4hr p53 24hr p53 4hr γH2AX 24hr γH2AX 24hr RNC 
      2AAF without S9 >311 >311 >311 >311 98 
2AAF with S9 >311 >311 119 35 184 
S9 Potentiation Ratio NC NC >2.6 >8.9 0.53 
      2AAN without S9 >55 >55 40 10.9 >55 
2AAN with S9 7.9 2.5 0.24 0.67 2.1 
S9 Potentiation Ratio 7 >22 167 16.3 >26.2 
      Anisomycin without S9 >2.5 >2.5 >2.5 2.1 0.08 
Anisomycin with S9 >14.1 >14.1 >14.1 >14.1 0.48 
S9 Potentiation Ratio NC NC NC <0.15 0.17 
      B[a]P without S9 >88 >88 >88 36 >88 
B[a]P with S9 >31 1.1 0.19 2x10^-5 2.8 
S9 Potentiation Ratio NC >80 >463 1.8x10^6 >31.4 
      Brefeldin A without S9 >0.5 >0.5 >0.5 >0.5 0.13 
Brefeldin A with S9 >356 >356 >356 >356 12.8 
S9 Potentiation Ratio NC NC NC NC 0.01 
      CCCP without S9 >35 >35 >35 >35 2.0 
CCCP with S9 >35 26 >35 >35 4.4 
S9 Potentiation Ratio NC >1.3 NC NC 0.45 
      CP without S9 >10,000 7,570 >10,000 5,523 5,981 
CP with S9 >156 8.7 99 1.7 7.5 
S9 Potentiation Ratio NC 870 >101 3,249 797 
      Cycloheximide without 
S9 >15 >15 >15 12 0.25 
Cycloheximide with S9 >15 >15 >15 >15 0.31 
S9 Potentiation Ratio NC NC NC <0.8 0.8 
      DB(a,l)P without S9 >50 >50 25 >50 >50 
DB(a,l)P with S9 0.9 0.052 0.0011 0.0013 0.041 
S9 Potentiation Ratio >56 >962 22,727 >38,462 >1,220 
      DEN without S9 >10,000 >10,000 >10,000 >10,000 >10,000 
DEN with S9 >10,000 >10,000 2,867 1,004 >10,000 
S9 Potentiation Ratio NC NC >3.5 >10 NC 
This article is protected by copyright. All rights reserved.
    
 
      DMBA without S9 >194 116 13.3 >194 98 
DMBA with S9 5.9 4.9 0.15 >194 4.5 
S9 Potentiation Ratio >32.9 23.7 88.7' NC 21.8 
      MMC without S9 0.802 0.0988 0.05031 0.00862 0.07407 
MMC with S9 1.576 0.136 0.06122 0.03391 0.2363 
S9 Potentiation Ratio 0.51 0.73 0.82 0.25 0.31 
      PhIP without S9 >178 >178 >178 >178 >178 
PhIP with S9 56.81 5.142 0.1093 0.2281 9.764 
S9 Potentiation Ratio >3.1 >34.6 >1,629 >780 >18.2 
      Resorcinol without S9 >12.5 2.6 6.6 0.79 0.59 
Resorcinol with S9 >71 24.6 25.8 14.4 12.6 
S9 Potentiation Ratio NC 0.11 0.26 0.05 0.047 
      Thapsigargin without S9 >21 >21 >21 >21 0.2 
Thapsigargin with S9 >15 >15 >15 >15 0.14 
S9 Potentiation Ratio NC NC NC NC 1.4 
 
--------- 
Abbreviations: Chemical abbreviations = same as Table I; BMD = benchmark dose; RNC = relative nuclei 
count; NC = not calculated 
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